The ULg thus becomes an official partner of the WHO, the United Nations and the Member States. From now on, the WHO can entrust the ULg with testing and quality control of the production of medicines of manufacturers, all over the world.
The WHO prequalification also enables the ULg to strengthen its services to national quality control laboratories in developing countries, thus contributing to the improvement of health systems in these countries by providing them with technical assistance, best practices (ISO, GMP …) and the training of the personnel of the pharmaceutical and control laboratories.
At the request of the WHO, the ULg is pursuing this mission more specifically in four African countries: the DR Congo, Burkina Faso, Benin and Rwanda. In addition, ULg is co-financed in Belgium by ARES for the organization of international training courses on the quality of medicines: it can now offer a WHO-labeled framework for trainees, particularly from Africa.
As a reference laboratory, ULg now has the opportunity to access major international surveys by the WHO, for example on HIV / AIDS, Anti-Malaria or Lifesaving Commodities. Together with the other prequalified laboratories, the ULg participates in a global network of excellence, exchanging information and good practices, particularly in the international fight against the falsification of medicines.
It is at the end of a sharp audit guaranteeing strict compliance with the most demanding international standards that the ULg has been awarded the WHO prequalification. This label shall be re-evaluated at least every three years.
Ultimately, the heads of the Department of Pharmacy hope to become a WHO Collaborative Center, which would be the highest international recognition of the ULg’s skills for quality control of the drug.
You might also like:
Watch Liège becoming a major healthcare hub
